Non-alcoholic fatty liver disease (NAFLD) is a spectrum of metabolic disorders that affects 25% of our global population. 20% of those with NAFLD develop non-alcoholic steatohepatitis (NASH), which can result in cirrhosis and liver cancer.

Despite continued research and development efforts, not one NASH therapeutic agent has made it to market yet. Traditional preclinical tests have repeatedly failed to predict human drug efficacy as they inadequately recreate the complexity and multifaceted nature of this human disease. As a result, NASH is poised to become a global health and economic burden.

Is it time to increase your chances of clinical success with a new human-relevant approach to drug discovery and development?